Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It was approved by the United States Food and Drug Administration (FDA) in November 2005. Deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
P450 (e.g. CYP17) inhibitor Related Products:
Ketoconazole; Orteronel(racemic); Orteronel; Cobicistat; Ozagrel; Ritonavir; Posaconazole; Voriconazole; Fluconazole; Clarithromycin; Abiraterone; Abiraterone acetate;